Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment
Serum and glucocorticoid-regulated kinase 1 (SGK1) is a serine/threonine kinase that is involved in various cellular pathways, such as ion transport, cell survival, proliferation, and immune responses. Dysregulation of this enzyme is increasingly being associated with the progression of 2 prominent...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Heart Rhythm O2 |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666501825000807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128466877349888 |
|---|---|
| author | Jamal E-Fatima, PhD Faez Iqbal Khan, PhD Dakun Lai, PhD |
| author_facet | Jamal E-Fatima, PhD Faez Iqbal Khan, PhD Dakun Lai, PhD |
| author_sort | Jamal E-Fatima, PhD |
| collection | DOAJ |
| description | Serum and glucocorticoid-regulated kinase 1 (SGK1) is a serine/threonine kinase that is involved in various cellular pathways, such as ion transport, cell survival, proliferation, and immune responses. Dysregulation of this enzyme is increasingly being associated with the progression of 2 prominent types of diseases, namely viral infections, such as COVID-19, and cardiovascular disorders, such as atrial fibrillation (AF), positioning it as a potential therapeutic target. With regard to coronavirus 2019 (COVID-19), SGK1 detrimentally affects inflammatory pathways and modulates the cytokine storm, leading to lung tissue damage. Considering this dysregulation, researchers are exploring SGK1 inhibition as a potential strategy for mitigating severe COVID-19 outcomes. SGK1 also regulates pumps and ion channels, significantly affecting cardiac performance in AF. This protein is responsible for promoting fibrosis and inflammation in the cardiac tissue, making it a potential target for reducing atrial fibrillation. SGK1 inhibition offers a new avenue for therapeutic targets against both COVID-19 and AF. This review is aimed at providing a comprehensive overview of SGK1 dysregulation in both diseases, underscoring the urgent need for more preclinical and clinical trials to evaluate effective SGK1 inhibitors for patients with coexisting COVID-19 and AF. |
| format | Article |
| id | doaj-art-620c11f848a84b45b7fdece7f0dcc694 |
| institution | OA Journals |
| issn | 2666-5018 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heart Rhythm O2 |
| spelling | doaj-art-620c11f848a84b45b7fdece7f0dcc6942025-08-20T02:33:18ZengElsevierHeart Rhythm O22666-50182025-05-016572073210.1016/j.hroo.2025.02.015Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatmentJamal E-Fatima, PhD0Faez Iqbal Khan, PhD1Dakun Lai, PhD2School of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Biosciences and Bioinformatics, Xi’an Jiaotong-Liverpool University, Suzhou, ChinaSchool of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu, China; Address reprint requests and correspondence: Professor Dakun Lai, School of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu, China.Serum and glucocorticoid-regulated kinase 1 (SGK1) is a serine/threonine kinase that is involved in various cellular pathways, such as ion transport, cell survival, proliferation, and immune responses. Dysregulation of this enzyme is increasingly being associated with the progression of 2 prominent types of diseases, namely viral infections, such as COVID-19, and cardiovascular disorders, such as atrial fibrillation (AF), positioning it as a potential therapeutic target. With regard to coronavirus 2019 (COVID-19), SGK1 detrimentally affects inflammatory pathways and modulates the cytokine storm, leading to lung tissue damage. Considering this dysregulation, researchers are exploring SGK1 inhibition as a potential strategy for mitigating severe COVID-19 outcomes. SGK1 also regulates pumps and ion channels, significantly affecting cardiac performance in AF. This protein is responsible for promoting fibrosis and inflammation in the cardiac tissue, making it a potential target for reducing atrial fibrillation. SGK1 inhibition offers a new avenue for therapeutic targets against both COVID-19 and AF. This review is aimed at providing a comprehensive overview of SGK1 dysregulation in both diseases, underscoring the urgent need for more preclinical and clinical trials to evaluate effective SGK1 inhibitors for patients with coexisting COVID-19 and AF.http://www.sciencedirect.com/science/article/pii/S2666501825000807Atrial fibrillationCOVID-19Cystic fibrosis transmembrane conductance regulatorEpithelial sodium channelSerum and glucocorticoid-regulated kinase 1 |
| spellingShingle | Jamal E-Fatima, PhD Faez Iqbal Khan, PhD Dakun Lai, PhD Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment Heart Rhythm O2 Atrial fibrillation COVID-19 Cystic fibrosis transmembrane conductance regulator Epithelial sodium channel Serum and glucocorticoid-regulated kinase 1 |
| title | Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment |
| title_full | Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment |
| title_fullStr | Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment |
| title_full_unstemmed | Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment |
| title_short | Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment |
| title_sort | exploring serum and glucocorticoid regulated kinase 1 a promising target for covid 19 and atrial fibrillation treatment |
| topic | Atrial fibrillation COVID-19 Cystic fibrosis transmembrane conductance regulator Epithelial sodium channel Serum and glucocorticoid-regulated kinase 1 |
| url | http://www.sciencedirect.com/science/article/pii/S2666501825000807 |
| work_keys_str_mv | AT jamalefatimaphd exploringserumandglucocorticoidregulatedkinase1apromisingtargetforcovid19andatrialfibrillationtreatment AT faeziqbalkhanphd exploringserumandglucocorticoidregulatedkinase1apromisingtargetforcovid19andatrialfibrillationtreatment AT dakunlaiphd exploringserumandglucocorticoidregulatedkinase1apromisingtargetforcovid19andatrialfibrillationtreatment |